Comments

CNBX Pharmaceuticals

CNBXOTCQB

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$0.006990

~0-0.14%

At Close: -

$0.009900

0.002941.63%

After Hours: May 7, 9:26 AM EDT

15 minutes delayed

CNBX Pharmaceuticals (CNBX) Forecast

News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

CNBX Pharmaceuticals (OTC:CNBX) Stock Quotes, Forecast and News Summary

CNBX Pharmaceuticals Stock (OTC: CNBX) stock price, news, charts, stock research, profile.

Open	$0.01
Close	$0.01
Volume / Avg.	277.60K / 231.50K
Day Range	0.01 - 0.01
52 Wk Range	0.01 - 0.05
Market Cap	$217.47K
P/E Ratio	0.02
Dividend Yield	-
Exchange	OTC
RSI	0
Short Interest	-
Days to Cover	1

Recent News

CNBX Acquires A Controlling Interest In Cancer Immunotherapy Developer

CNBX Pharmaceuticals Inc. (OTCQB: CNBX) has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd. The TaGeza research team remains committed to the company, and co-founder professor Benjamin Dekel (MD, PhD) will continue to serve as the company's chief scient

Vuk Zdinjak

Cannabics Pharmaceuticals Changes Name To CNBX Pharmaceuticals, Moves Ahead With Cancer Treatment Drug Research

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) has changed its corporate name to "CNBX Pharmaceuticals Inc."

Vuk Zdinjak

Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer

Cannabics Pharmaceuticals Inc.

Maureen Meehan

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

About CNBX Pharmaceuticals Inc

Sector

Health Care

Industry

Pharmaceuticals

CNBX Pharmaceuticals Inc is a biotechnology company. It develops pharmaceuticals focusing on cancer ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.